AroCell AB: AroCell signs distribution agreement with Eagle Biosciences in the United States

Uppsala October 6, 2016                                                                PRESS RELEASE

AroCell signs distribution agreement with Eagle Biosciences in the United States

AroCell AB (publ) announced today that a distribution agreement has been signed with the New England-based company Eagle Biosciences, for distribution of the AroCell TK 210 ELISA test in North America.

The TK 210 ELISA test measures TK1 protein levels for valuable information about the speed of cell turnover. As tumors have high cell turnover, the test may provide valuable information for prognosis and optimization of treatment strategy.

"We are delighted to partner with Eagle Biosciences for the distribution of the TK 210 ELISA test", states Jan Stålemark, AroCell CEO. "Eagle Biosciences is a leading provider of ELISA assay kits in North America, and has primary focus on providing innovative products that aid medical research and clinical laboratories. This highly concurs with our strategy to make the TK 210 ELISA test widely available for investigational use in the US, in order to facilitate use of the product in cancer research institutions as well as within the pharmaceutical industry".

The TK 210 ELISA test will be commercially available immediately through Eagle Biosciences for investigational use only in the United States.

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206
info@arocell.com
www.arocell.com

About AroCell
AroCell AB (AROC) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please seewww.arocell.com. This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through Jan Stålemark, at 11.45  CET on 6th October 2016. Redeye is AroCell:s Certified Adviser